je.st
news
Tag: merck announces
Merck Announces First Presentation of Data on the Investigational Use of KEYTRUDA (pembrolizumab) in Patients with Advanced Gastric Cancer at ESMO 2014
2014-09-28 09:15:00| Merck.com - Corporate News
Dateline City: WHITEHOUSE STATION, N.J. KEYTRUDA monotherapy achieved 31 percent overall response rate in patients with PD-L1 positive, advanced gastric cancer Phase 2 study to be initiated in first quarter of 2015 (KEYNOTE-059) WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the first presentation of data on the investigational use of KEYTRUDA (pembrolizumab) the companys anti-PD-1 therapy in PD-L1 positive, advanced gastric cancer. The early findings presented showed an overall response rate (confirmed and unconfirmed) of 31 percent with KEYTRUDA as monotherapy, as measured by investigator assessed, RECIST v1.1 (n= 12/39: 95% CI, 17-47). Language: English Contact: MerckMedia:Ian McConnell, 973-901-5722orClaire Mulhearn, 908-423-7425orInvestor:Joseph Romanelli, 908-423-5185orJustin Holko, 908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: with
data
advanced
presentation
Merck Announces Data from Pivotal Phase 3 Fracture Outcomes Study for Odanacatib, an Investigational Oral, Once-Weekly Treatment for Osteoporosis
2014-09-15 19:30:00| Merck.com - Product News
Dateline City: WHITEHOUSE STATION, N.J. Merck now expects to submit the New Drug Application for odanacatib with the U.S. Food and Drug Administration (FDA) in 2015 WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced data from the pivotal Phase 3 fracture outcomes study for odanacatib in postmenopausal women with osteoporosis. Odanacatib is Mercks investigational once-weekly cathepsin K inhibitor. In the Long-Term Odanacatib Fracture Trial (LOFT), odanacatib met its primary endpoints and significantly reduced the risk of osteoporotic hip, spine and non-vertebral fractures compared with placebo. Language: English Contact: MerckMedia:Pam Eisele, 267-305-3558Tracy Ogden, 215-370-5597orInvestors:Justin Holko, 609-915-8293 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: for
data
study
treatment
Merck Announces Second-Quarter 2014 Financial Results
2014-07-29 12:56:00| Merck.com - Corporate News
Dateline City: WHITEHOUSE STATION, N.J. Second-Quarter 2014 Non-GAAP EPS of $0.85, Excluding Certain Items, and GAAP EPS of $0.68 2014 Full-Year Non-GAAP EPS Target of $3.43 to $3.53, Excluding Potential Venezuelan Bolivar Devaluation and Certain Other Items; 2014 Full-Year GAAP EPS Target of $4.44 to $4.77 2014 Full-Year Non-GAAP EPS Target Includes $0.06 to $0.09 Anticipated Dilution From Planned Sale of Merck Consumer Care and Research Collaboration With Bayer, and Planned Acquisition of Idenix Generated Worldwide Sales of $10.9 Billion, a Decrease of 1 Percent, Reflecting Unfavorable Impact of Patent Expiries, Divested Products and Decline in Sales of Hepatitis C Products Grew Top Five Franchises by 6 Percent in Total Pembrolizumab (MK-3475), an Investigational Anti-PD-1 Antibody, Accepted in Second Quarter for Regulatory Review in Both the United States and European Union WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced financial results for the second quarter of 2014. Language: English Contact: MerckMedia:Steve Cragle, 908-423-3461Lainie Keller, 908-423-4187orInvestors:Joe Romanelli, 908-423-5185Justin Holko, 908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: results
financial
announces
merck
Merck Announces Fourth-Quarter 2014 Dividend
2014-07-23 18:15:00| Merck.com - Corporate News
Dateline City: WHITEHOUSE STATION, N.J. WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the Board of Directors has declared a quarterly dividend of $0.44 per share of the companys common stock for the fourth quarter of 2014. Payment will be made on October 7, 2014, to stockholders of record at the close of business on September 15, 2014. About Merck Language: English Contact: MerckMedia:Lainie Keller, 908-423-4187orInvestors:Justin Holko, 908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: announces
dividend
merck
announces fourthquarter
Merck Announces Data from Investigational Phase 3 Study on EMEND (aprepitant) for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Children Undergoing Emetogenic Chemotherapy
2014-06-30 14:00:00| Merck.com - Research & Development News
Dateline City: WHITEHOUSE STATION, N.J. Merck Planning Regulatory Submissions in the U.S. for EMEND in Pediatric Setting Including New Suspension Formulation in Second Half of 2014 WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced results from a global, investigational Phase 3 study to evaluate the safety and efficacy of EMEND (aprepitant) in the prevention of chemotherapy-induced nausea and vomiting (CINV) in pediatric cancer patients, aged 6 months to 17 years. Language: English Contact: MerckMedia:Pam Eisele, 267-305-3558orClaire Mulhearn, 908-423-7425orInvestors:Joseph Romanelli, 908-423-5185orJustin Holko, 908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: data
study
children
phase
Sites : [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] next »